clinical trial · NCT05462756
A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections
Eli Lilly and Company·phase3·completed·n = 730
Type 2 DiabetesType 2 Diabetes Treated With InsulinInsulin Efsitora AlfaInsulin Lispro (U100)Insulin Glargine (U100)
brief summary
The reason for this study is to evaluate if the once-weekly study drug insulin efsitora alfa (LY3209590) is safe and effective compared with daily insulin glargine in participants with Type 2 diabetes (T2D) that have already been treated with basal insulin and at least 2 injections per day of prandial insulin. The study consists of a 3-week screening/lead-in period, a 26-week treatment period and a 5-week safety follow-up period. The study will last up to 34 weeks.
started
Aug 11, 2022
primary completion
Feb 27, 2024
completion
Feb 27, 2024
last updated
Apr 27, 2025
official title
A Phase 3, Parallel-Design, Open-Label, Randomized Controlled Study to Evaluate the Efficacy and Safety of LY3209590 as a Weekly Basal Insulin Compared to Insulin Glargine in Adults With Type 2 Diabetes on Multiple Daily Injections
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol